Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa

被引:266
|
作者
Molloy, S. F. [1 ]
Kanyama, C. [5 ]
Heyderman, R. S. [2 ,6 ,7 ]
Loyse, A. [1 ]
Kouanfack, C. [9 ,10 ]
Chanda, D. [12 ,13 ]
Mfinanga, S. [16 ]
Temfack, E. [11 ,17 ]
Lakhi, S. [13 ]
Lesikari, S. [16 ]
Chan, A. K. [8 ,19 ]
Stone, N. [1 ,12 ,13 ]
Kalata, N. [6 ,7 ]
Karunaharan, N. [1 ,12 ,13 ]
Gaskell, K. [6 ,7 ]
Peirse, M. [6 ,7 ]
Ellis, J. [6 ,7 ]
Chawinga, C. [5 ]
Lontsi, S. [10 ]
Ndong, J. -G. [10 ]
Bright, P. [8 ,12 ,13 ]
Lupiya, D. [8 ]
Chen, T. [4 ]
Bradley, J. [3 ]
Adams, J. [1 ]
Van der Horst, Charles [5 ,20 ]
van Oosterhout, J. J. [8 ]
Sini, V. [10 ]
Mapoure, Y. N. [11 ]
Mwaba, P. [14 ,15 ]
Bicanic, T. [1 ]
Lalloo, D. G. [4 ]
Wang, D. [4 ]
Hosseinipour, M. C. [5 ,20 ]
Lortholary, O. [17 ,18 ]
Jaffar, S. [4 ]
Harrison, T. S. [1 ,5 ]
机构
[1] St Georges Univ London, Inst Infect & Immun, Ctr Global Hlth, London, England
[2] UCL, London, England
[3] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London, England
[4] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England
[5] Univ North Carolina Project, Kamuzu Cent Hosp, Lilongwe, Malawi
[6] Liverpool Wellcome Trust Clin Res Programm, Liverpool, Merseyside, England
[7] Univ Malawi, Coll Med, Blantyre, Malawi
[8] Zomba Cent Hosp, Dignitas Int, Zomba, Malawi
[9] Univ Dschang, Dschang, Cameroon
[10] Agence Natl Rech Sida, Hop Cent Yaounde Site, Yaounde, Cameroon
[11] Douala Gen Hosp, Douala, Cameroon
[12] Inst Med Res & Training, Lusaka, Zambia
[13] Univ Teaching Hosp, Lusaka, Zambia
[14] Lusaka Apex Med Univ, Dept Internal Med, Lusaka, Zambia
[15] Lusaka Apex Med Univ, Directorate Res & Postgrad Studies, Lusaka, Zambia
[16] Natl Inst Med Res, Muhimbili Med Res Ctr, Dar Es Salaam, Tanzania
[17] Inst Pasteur, Mol Mycol Unit, Paris, France
[18] Paris Descartes Univ, Necker Pasteur Ctr Infect Dis & Trop Med, AP HP, IHU Imagine, Paris, France
[19] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Infect Dis, Toronto, ON, Canada
[20] Univ N Carolina, Chapel Hill, NC USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 11期
基金
美国国家卫生研究院; 英国医学研究理事会; 英国惠康基金;
关键词
HIGH-DOSE FLUCONAZOLE; COURSE AMPHOTERICIN-B; COMBINED COHORT; GLOBAL BURDEN; FLUCYTOSINE; THERAPY; DISEASE; TRIAL;
D O I
10.1056/NEJMoa1710922
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Cryptococcal meningitis accounts for more than 100,000 human immunodeficiency virus (HIV)-related deaths per year. We tested two treatment strategies that could be more sustainable in Africa than the standard of 2 weeks of amphotericin B plus flucytosine and more effective than the widely used fluconazole monotherapy. METHODS We randomly assigned HIV-infected adults with cryptococcal meningitis to receive an oral regimen (fluconazole [1200 mg per day] plus flucytosine [100 mg per kilogram of body weight per day] for 2 weeks), 1 week of amphotericin B (1 mg per kilogram per day), or 2 weeks of amphotericin B (1 mg per kilogram per day). Each patient assigned to receive amphotericin B was also randomly assigned to receive fluconazole or flucytosine as a partner drug. After induction treatment, all the patients received fluconazole consolidation therapy and were followed to 10 weeks. RESULTS A total of 721 patients underwent randomization. Mortality in the oral-regimen, 1-week amphotericin B, and 2-week amphotericin B groups was 18.2% (41 of 225), 21.9% (49 of 224), and 21.4% (49 of 229), respectively, at 2 weeks and was 35.1% (79 of 225), 36.2% (81 of 224), and 39.7% (91 of 229), respectively, at 10 weeks. The upper limit of the one-sided 97.5% confidence interval for the difference in 2-week mortality was 4.2 percentage points for the oral-regimen group versus the 2-week amphotericin B groups and 8.1 percentage points for the 1-week amphotericin B groups versus the 2-week amphotericin B groups, both of which were below the predefined 10-percentage-point noninferiority margin. As a partner drug with amphotericin B, flucytosine was superior to fluconazole (71 deaths [31.1%] vs. 101 deaths [45.0%]; hazard ratio for death at 10 weeks, 0.62; 95% confidence interval [CI], 0.45 to 0.84; P = 0.002). One week of amphotericin B plus flucytosine was associated with the lowest 10-week mortality (24.2%; 95% CI, 16.2 to 32.1). Side effects, such as severe anemia, were more frequent with 2 weeks than with 1 week of amphotericin B or with the oral regimen. CONCLUSIONS One week of amphotericin B plus flucytosine and 2 weeks of fluconazole plus flucytosine were effective as induction therapy for cryptococcal meningitis in resourcelimited settings.
引用
收藏
页码:1004 / 1017
页数:14
相关论文
共 50 条
  • [1] Antifungal treatment for cryptococcal meningitis
    Powderly, WG
    [J]. INTERNAL MEDICINE JOURNAL, 2006, 36 (07) : 404 - 405
  • [2] Antifungal therapy for treatment of cryptococcal meningitis
    姚志荣
    廖万清
    温海
    [J]. ChineseMedicalJournal., 2000, (02)
  • [3] Antifungal therapy for treatment of cryptococcal meningitis
    姚志荣
    廖万清
    温海
    [J]. 中华医学杂志(英文版), 2000, (02) : 82 - 84
  • [4] Antifungal therapy for treatment of cryptococcal meningitis
    Yao, ZR
    Liao, WQ
    Wen, H
    [J]. CHINESE MEDICAL JOURNAL, 2000, 113 (02) : 178 - 180
  • [5] Improving cryptococcal meningitis treatment in Africa
    Makoni, Munyaradzi
    [J]. LANCET MICROBE, 2022, 3 (06): : E406 - E406
  • [6] Cryptococcal Antigen Screening and Early Antifungal Treatment to Prevent Cryptococcal Meningitis: A Review of the Literature
    Kaplan, Jonathan E.
    Vallabhaneni, Snigdha
    Smith, Rachel M.
    Chideya-Chihota, Sekai
    Chehab, Joel
    Park, Benjamin
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 : S331 - S339
  • [7] COMBINATION ANTIFUNGAL THERAPY FOR CRYPTOCOCCAL MENINGITIS
    TOBIAS, JS
    WRIGLEY, PFM
    SHAW, E
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1976, 52 (607) : 305 - 308
  • [8] Combination Antifungal Therapy for Cryptococcal Meningitis
    Day, Jeremy N.
    Chau, Tran T. H.
    Wolbers, Marcel
    Mai, Pham P.
    Dung, Nguyen T.
    Mai, Nguyen H.
    Phu, Nguyen H.
    Nghia, Ho D.
    Phong, Nguyen D.
    Thai, Cao Q.
    Thai, Le H.
    Chuong, Ly V.
    Sinh, Dinh X.
    Duong, Van A.
    Hoang, Thu N.
    Diep, Pham T.
    Campbell, James I.
    Sieu, Tran P. M.
    Baker, Stephen G.
    Chau, Nguyen V. V.
    Hien, Tran T.
    Lalloo, David G.
    Farrar, Jeremy J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (14): : 1291 - 1302
  • [9] Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis
    Tu, Jie
    Li, Zhuang
    Jiang, Yanjuan
    Ji, Changjin
    Han, Guiyan
    Wang, Yan
    Liu, Na
    Sheng, Chunquan
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (05) : 2376 - 2389
  • [10] One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi
    Kanyama, Cecilia
    Molloy, Sile F.
    Chan, Adrienne K.
    Lupiya, Duncan
    Chawinga, Chimwemwe
    Adams, Jack
    Bright, Philip
    Lalloo, David G.
    Heyderman, Robert S.
    Lortholary, Olivier
    Jaffar, Shabbar
    Loyse, Angela
    van Oosterhout, Joep J.
    Hosseinipour, Mina C.
    Harrison, Thomas S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 70 (03) : 521 - 524